- Citations, last 5 years
- 78
- Works, last 5 years
- 11
- h-index
- 26
- Scientists listed
- 3
- Grants since 2016
- 60
Grants received
2018–2021 · research · R44
Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2018–2021 · cooperative agreement · UT2
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
Jake Reder · Celdara Medical (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma
Yolanda Camille Nesbeth · Celdara Medical (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Specificity and safety of a targeted therapy against triple negative breast cancer
Irena Ivanovska · Celdara Medical (United States) · funded by National Institutes of Health
2017–2026 · research · R42
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Development of GIFT4: a B cell focused immunotherapy for cancer
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of GIFT4: a B cell focused immunotherapy for cancer
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Cellular Immunotherapy for Systemic Sclerosis
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2017–2021 · research · R41
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2017–2018 · research · R43
Cellular Immunotherapy for SSc
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2017–2019 · research · R41
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2017–2019 · research · R41
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2017–2026 · research · R42
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Cellular Immunotherapy for Systemic Sclerosis
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2017–2018 · research · R43
Complex 3-Dimensional in Vitro Human Skin Tissue Models for Scleroderma
Michael W Fanger · Celdara Medical (United States) · funded by National Institutes of Health
2017–2026 · research · R42
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
